# Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects

> **NCT02546310** · PHASE1 · COMPLETED · sponsor: **Nxera Pharma UK Limited** · enrollment: 54 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** HTL0009936
- **DRUG:** HTL0009936 matching placebo

## Key facts

- **NCT ID:** NCT02546310
- **Lead sponsor:** Nxera Pharma UK Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2017-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546310, "Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02546310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*